CSTL Earnings Results and History
Castle Biosciences Inc's earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- Adjusted EPS−$0.13 vs −$0.35 est +62.6%
- GAAP EPS−$0.13
- Revenue$102.9M vs $92.8M est +10.9%
- Revenue growth+23.9% vs a year ago
- Outlook RaisedFY2026: $385M to $395M revenue
Filed ยท Press release
Key takeaways
from the press release- Q3 revenue rose 24% year over year to $102.9 million, with total core test reports up 22%.
- TissueCypher Barrett's Esophagus test reports grew 47% year over year to 15,574, driving the top-line gain.
EPS by quarter
GAAP diluted, 12 quartersRevenue and operating margin
from 10-Q and 10-KQuarter by quarter
from 10-Q and 10-K filings| Quarter ended | Revenue | Growth | Gross margin | Op margin | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2026 | $102.9M | +23.9% | 76.8% | −2.7% | −$4.1M | −$0.13 | $12.2M |
| Jun 2026 | $103.5M | +20.1% | 77.1% | −3.0% | −$2.1M | −$0.07 | $6.6M |
| Mar 2026 | $83.7M | −4.9% | 75.5% | −22.0% | −$14.5M | −$0.49 | −$34.6M |
| Dec 2025 | $87M | +0.8% | 79.0% | −4.4% | −$2.3M | −$0.07 | $19.7M |
EPS here is GAAP diluted, as filed with the SEC. Estimates are usually based on adjusted EPS, so the two can differ. Growth compares with the same quarter a year earlier.
Year by year
fiscal years, from 10-K filings| Year ended | Revenue | Growth | Op margin | Net income | EPS |
|---|---|---|---|---|---|
| Dec 31, 2025 | $344.2M | +3.7% | −12.4% | −$24.2M | −$0.83 |
| Dec 31, 2024 | $332.1M | +51.1% | 2.6% | $18.2M | $0.62 |
| Dec 31, 2023 | $219.8M | +60.4% | −30.9% | −$57.5M | −$2.14 |
| Dec 31, 2022 | $137M | +45.7% | −53.2% | −$67.1M | −$2.58 |
| Dec 31, 2021 | $94.1M | – | −42.6% | −$31.3M | −$1.24 |
Filings and dates
SEC EDGAR- Nov 5, 2026Earnings release, Q3 20268-K Press release
- Nov 5, 2026Quarterly report10-Q All filings
Also see CSTL institutional ownership and the earnings calendar.
CSTL earnings FAQ
What were CSTL's latest earnings?
For Q3 2026 Castle Biosciences Inc reported revenue of $102.9M, GAAP EPS of -$0.13 and adjusted EPS of -$0.13. The results were filed with the SEC on Nov 5, 2026.
When is CSTL's next earnings date?
There is no confirmed date on our calendar yet. Most companies report about four to six weeks after each quarter ends.
Is CSTL's revenue growing?
In the quarter ended Sep 30, 2026 revenue was $102.9M, up 23.9% from a year earlier. The table on this page shows every quarter from the company's 10-Q and 10-K filings.
Where do these numbers come from?
Results, guidance and financials come from Castle Biosciences Inc's own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.